Molecular fine tuning of the PCa genomic landscape by reprogramming of testosterone metabolites, HSD17B2, HSD17B3, SHBG, and SRD5A1 holds the promise of profoundly altering the tumor microenvironment (TME), suppressing angiogenesis, and enhancing susceptibility of the cancerous cells to immunosurveillance [13,14,15]. Here, SRD5A1 is linked to posterior cortical atrophy.